Abstract |
In May 2018, following the preliminary results of a study in Botswana that reported congenital anomalies in babies born to HIV-positive women taking dolutegravir drug, the WHO issued a teratogenicity alert. However, there are scarce data on the impact of this guidance on contraceptive uptake among women taking dolutegravir. We assessed the uptake of contraceptives in HIV-positive women of reproductive age on dolutegravir regimens. |
Year of Publication |
2022
|
Volume |
22
|
Issue |
1
|
Number of Pages |
262+
|
Date Published |
2022/06/27
|
ISBN Number |
1472-6874
|
URL |
https://doi.org/10.1186/s12905-022-01842-7
|
DOI |
10.1186/s12905-022-01842-7
|